EP3143995

NOVARTIS AG
Application Number
EP16186041A
Filing Date
Feb 18, 2002
Status
Granted And Under Opposition
Nov 2, 2018
Grant Date
Dec 5, 2018
External Links
Slate, Register

Biblio Summary

The patent EP3143995B1 was granted on Dec 5, 2018 by Novartis Ag The patent is currently Granted And Under Opposition.

The table below shows 7 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCARE LTDSep 5, 2019ADMISSIBLE
GENERICS UKSep 5, 2019WITHDRAWN
STADASep 5, 2019WITHDRAWN
ZENTIVA K.S.Sep 3, 2019ADMISSIBLE
TEVAAug 30, 2019ADMISSIBLE
SYNTHON B.V.Aug 27, 2019ADMISSIBLE
ETHYPHARMJun 12, 2019ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245